Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07172464 · ClinicalTrials.gov registry record · NA
Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study
A NA study of Patent Foramen Ovale and PFO - Patent Foramen Ovale, sponsored by Recross Cardio.
- Recruiting
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT07172464 is a NA study of Patent Foramen Ovale and PFO - Patent Foramen Ovale that is actively recruiting participants, run by Recross Cardio. The registered enrollment target is 15 participants, below the 419-participant average among 7 other Patent Foramen Ovale trials with a reported enrollment target (96% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT07172464, a NA study of Patent Foramen Ovale and PFO - Patent Foramen Ovale, is actively recruiting participants, sponsored by Recross Cardio.
- RECRUITING
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it aims to answer is: • Is the P3 Occluder System safe and effective for closing a PFO in patients who have had a stroke that could be related to a PFO. Participants will: * Undergo the procedure to implant the P3 Occluder System, if deemed appropriate. * Visit their doctor at 1 month, 3 months, 6 months, 1 year, and 5 years after the procedure for follow up exams. * Answer a phone call from study staff at 2 years, 3 years, and 4 years after the procedure to answer a survey.
Conditions Studied
Interventions
- DEVICE Recross P3 Occluder (P3O) System
Study Locations (5)
California
- UCLA - Los Angeles
Florida
- The Cardiac and Vascular Institute - Gainesville
Massachusetts
- Tufts Medical Center - Boston
New York
- Columbia University Medical Center/ NewYork Presbyterian Hospital - New York
South Carolina
- Prisma Health - Upstate - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2025-10-09 |
| Est. Completion | 2031-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07172464
The ClinicalTrials.gov registry entry for NCT07172464 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 419-participant average among 7 other Patent Foramen Ovale trials with a reported enrollment target (96% lower). The listed sponsor is Recross Cardio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Patent Foramen Ovale appearing as the primary indexed condition, and to 1 intervention - of which Recross P3 Occluder (P3O) System is the first listed.
NCT07172464 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07172464 about?
NCT07172464 is a clinical study titled "Early Feasibility Study (EFS) Evaluating Percutaneous Repair of the Atrial Septum With a Novel PFO Occluder: The PROTEA-PFO Study". The goal of this clinical trial is to test a new heart device called P3 Occluder System in patients who have a small opening between the upper chambers of the heart (called a Patent Foramen Ovale or PFO) and have experienced a stroke that may be related to this heart opening. The main question it ai...
What is the current status of trial NCT07172464?
This trial is currently recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2025-10-09. Estimated completion is 2031-02.
What conditions does trial NCT07172464 study?
This clinical trial studies the following conditions: Patent Foramen Ovale, PFO - Patent Foramen Ovale, Cryptogenic Stroke, PFO, PFO-associated Stroke.
What interventions are being tested in trial NCT07172464?
The interventions under investigation include: Recross P3 Occluder (P3O) System (DEVICE).
Who is sponsoring clinical trial NCT07172464?
This trial is sponsored by Recross Cardio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07172464 being conducted?
This trial has 5 study locations across California, Florida, Massachusetts, New York, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Patent Foramen Ovale
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Encore PFO Closure Device - The PerFOrm Trial
RECRUITING · NA
-
AMPLATZER PFO Occluder Post Approval Study
ACTIVE NOT RECRUITING · NA
-
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
ACTIVE NOT RECRUITING · NA
-
Is Blood Flow Through IPAVA and PFO Related to Breath-hold and SCUBA Diving-induced Pulmonary Hypertension?
COMPLETED · Early Phase 1
-
Comorbidities Associated With Migraine and Patent Foramen Ovale (CAMP)
COMPLETED
-
Does Patent Foramen Ovale Size Matter in Men and Women
COMPLETED
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.